Sven Zimmermann, a molecular biologist with experience in investment banking, has been appointed chief executive of Inotrem, effective 19 April. France-based Inotrem has a lead product in separate clinical trials for septic shock and severe Covid-19. Dr Zimmermann joins the company from MetrioPharm AG, a Swiss biotech, where he was chief financial officer. His earlier industry roles included work in mergers and acquisitions and an initial public offering on the US Nasdaq market. Dr Zimmermann holds a PhD in molecular biology from the University of Zurich, Switzerland.
Inotrem announced the appointment on 24 March 2021.
Copyright 2021 Evernow Publishing Ltd